Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma
about
Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing researchClinical applications of gamma delta T cells with multivalent immunity.IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity.Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases.T cell homing therapy for reducing regulatory T cells and preserving effector T cell function in large solid tumors.Morphofunctional Characteristics of Human Lymphocytes after In Vitro Activation.4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy.
P2860
Q26866122-787DD0B7-2370-469B-9F88-66DAA8AA845EQ34677859-04974C20-0322-4732-B1F6-6F4974109E83Q35979037-929D3ED9-B554-4EFD-B988-0F4E554D2532Q36710982-56CC80A8-BB54-4B11-AA5A-98C327E41E5BQ37043492-4749B092-E14D-4228-B81B-83F0D0CEA6EAQ37109545-AF4251EF-8E67-4D4C-AF5B-AAECC8D5CA3BQ41203830-28F4DCC2-CB79-473B-AA0F-B0D12D238ED4Q43147493-6E1025BD-1D11-46A2-81B1-B8319F0D6FAEQ46550701-2BE9FEAD-6213-4D45-A193-DAC803F77262Q46863819-10BAFEF9-1B63-4271-9B07-9C2108EA0FCEQ46884989-8554750F-A98F-4BB5-B206-8169330284C5Q49390588-B98245A2-CFDA-47A1-8233-F08D84FA4C9FQ51430363-D7AE94AC-DF5A-4F58-891C-E428DBED569CQ54139665-D6D5AF3F-2E86-41FB-95B6-6BDBF445E2E9Q55315844-9BA8D062-4A99-4950-A805-01912F6365AA
P2860
Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Activation and propagation of ...... tive immunotherapy of melanoma
@ast
Activation and propagation of ...... tive immunotherapy of melanoma
@en
Activation and propagation of ...... tive immunotherapy of melanoma
@nl
type
label
Activation and propagation of ...... tive immunotherapy of melanoma
@ast
Activation and propagation of ...... tive immunotherapy of melanoma
@en
Activation and propagation of ...... tive immunotherapy of melanoma
@nl
prefLabel
Activation and propagation of ...... tive immunotherapy of melanoma
@ast
Activation and propagation of ...... tive immunotherapy of melanoma
@en
Activation and propagation of ...... tive immunotherapy of melanoma
@nl
P2093
P2860
P1476
Activation and propagation of ...... tive immunotherapy of melanoma
@en
P2093
Cara Haymaker
Chantale Bernatchez
Charuta Kale
Christopher Toth
Francesco M Marincola
Helen Huls
Laszlo G Radvanyi
Laurence J N Cooper
P2860
P304
P356
10.1097/CJI.0000000000000056
P577
2014-11-01T00:00:00Z